VA-LINEAGE-LOGISTICS
Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the opening of its newest fully automated facility strategically located near the Port of Virginia’s world-renowned Virginia International Gateway in Portsmouth which offers an integrated network of highways, air, rail, and sea services.
The new state-of-the-art cold storage warehouse joins Lineage’s growing network of over 22 fully automated facilities worldwide. The Company’s growing automation presence comes at a critical time for the cold chain sector as the pandemic accelerated much-needed change to operations and systems within the decades-old cold storage industry. Lineage’s industry-leading automation technology increases storage density, maximizes capacity, provides real-time inventory management, and keeps food safe all while reducing energy consumption.
“As a testament to the power of public-private partnership, we are so pleased to announce the opening of our state-of-the-art facility in Portsmouth,” said Brian Beattie, Senior Vice President of Sale at Lineage Logistics. “Lineage’s innovative technology used in the Portsmouth warehouse will help our customers address rising supply chain demands both nationally and internationally while contributing to the ongoing economic development and job development in the region.”
Portsmouth Economic Development alongside the Virginia Economic Development Partnership, the Portsmouth Ports & Industrial Commission, and the Virginia Port Authority worked to secure the project for Lineage, which in the end resulted in the $84 million investment, produced over 80 high-paying jobs with a Portsmouth-first plan, and remediated a former chemical plant site that was previously vacant – all of which have benefited and will continue to support the city’s economic expansion.
“Portsmouth is thrilled to welcome Lineage Logistics to our business community,” said Shannon E. Glover, Mayor of Portsmouth. “Lineage has already become a wonderful community partner with its participation in our Portsmouth@Work programs, its commitment to supporting Portsmouth residents and businesses, and in the redevelopment of a key brownfield site. We look forward to Lineage continuing to grow in Portsmouth.”
The 167,264 square-foot facility, which is adjacent to the Virginia International Gateway, provides Lineage with access to key markets and will serve as a critical hub to connect people with food around the world. The facility will also aid in strengthening the supply chain and logistics infrastructure in Portsmouth as well as address the growing demand for cold storage in the region. The facility includes 26,000 pallet positions and blast freezing capabilities.
“This new cold storage facility is an important regional asset that is going to create jobs, provide greater flexibility to movers of cold cargo and help increase volumes of cold cargo moving across The Port of Virginia,” said Stephen A. Edwards, CEO and Executive Director of the Virginia Port Authority. “When we expanded and optimized Virginia International Gateway [just two years ago] we added a significant amount of capacity to handle cold cargo. Lineage’s new facility, which isn’t far from the gates at VIG, is going to help directly support our investment and make the port a destination for movers of cold cargo. We look forward to working with Lineage Logistics and helping to maximize its investment here.”
At 10:30 AM EST today, leaders from Lineage Logistics will be joined by Portsmouth community leaders and business partners, including Senator Louise Lucas, Secretary Brian Ball and Portsmouth Mayor Shannon Glover, to celebrate the hard work of the teams who transformed the facility from concept to reality. The event will include a ribbon-cutting ceremony, followed by group tours of the facility.
About Lineage Logistics
Lineage Logistics is the world’s largest temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 15 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005235/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom